Vaccinex Statistics
Total Valuation
Vaccinex has a market cap or net worth of 3.24 million. The enterprise value is 1.91 million.
| Market Cap | 3.24M |
| Enterprise Value | 1.91M |
Important Dates
The next estimated earnings date is Thursday, March 20, 2025.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Vaccinex has 2.68 million shares outstanding. The number of shares has increased by 480.32% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 2.68M |
| Shares Change (YoY) | +480.32% |
| Shares Change (QoQ) | +11.52% |
| Owned by Insiders (%) | 0.40% |
| Owned by Institutions (%) | 1.01% |
| Float | 986,629 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.82 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -0.10 |
| EV / Sales | 4.93 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -0.12 |
Financial Position
The company has a current ratio of 0.77
| Current Ratio | 0.77 |
| Quick Ratio | 0.63 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.00 |
| Interest Coverage | n/a |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -342.96% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 9,949 |
| Profits Per Employee | -476,333 |
| Employee Count | 40 |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -84.84% in the last 52 weeks. The beta is 1.10, so Vaccinex's price volatility has been similar to the market average.
| Beta (5Y) | 1.10 |
| 52-Week Price Change | -84.84% |
| 50-Day Moving Average | 3.19 |
| 200-Day Moving Average | 5.21 |
| Relative Strength Index (RSI) | 28.34 |
| Average Volume (20 Days) | 103,585 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.51 |
Income Statement
In the last 12 months, Vaccinex had revenue of 388,000 and -18.58 million in losses. Loss per share was -12.02.
| Revenue | 388,000 |
| Gross Profit | -16.19M |
| Operating Income | -20.34M |
| Pretax Income | -18.58M |
| Net Income | -18.58M |
| EBITDA | -20.23M |
| EBIT | -20.34M |
| Loss Per Share | -12.02 |
Balance Sheet
The company has 2.91 million in cash and 59,000 in debt, giving a net cash position of 2.85 million or 1.06 per share.
| Cash & Cash Equivalents | 2.91M |
| Total Debt | 59,000 |
| Net Cash | 2.85M |
| Net Cash Per Share | 1.06 |
| Equity (Book Value) | -1.32M |
| Book Value Per Share | -1.09 |
| Working Capital | -1.42M |
Cash Flow
In the last 12 months, operating cash flow was -15.85 million and capital expenditures -22,000, giving a free cash flow of -15.87 million.
| Operating Cash Flow | -15.85M |
| Capital Expenditures | -22,000 |
| Free Cash Flow | -15.87M |
| FCF Per Share | -5.93 |
Margins
| Gross Margin | n/a |
| Operating Margin | -5,241.24% |
| Pretax Margin | -4,787.89% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Vaccinex does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -480.32% |
| Shareholder Yield | -480.32% |
| Earnings Yield | -993.80% |
| FCF Yield | -489.95% |
Stock Splits
The last stock split was on February 20, 2024. It was a reverse split with a ratio of 0.0714286.
| Last Split Date | Feb 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 0.0714286 |
Scores
Vaccinex has an Altman Z-Score of -115.62. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -115.62 |
| Piotroski F-Score | n/a |